With The End Of Pfizergan, Pfizer Has To Grow It Alone
This article was originally published in The Pink Sheet Daily
Investors are wondering what Pfizer might do next – and especially whether or not it will split – after the company is outmaneuvered by the US government and ends its ambition to merge with Allergan.
You may also be interested in...
US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.